LobbyingMarshall Bioresources lobbying by quarter
Marshall Bioresources's latest lobbying report covers Q2 2026, at $50K. Its first report covers Q2 2026; the issues it reports most are Health Issues.
Marshall Bioresources
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $50K
- Last 2 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q2 2026
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q2 2026 | $50K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$50K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Food & Drug Administration (FDA)1 reports
- Health & Human Services, Dept of (HHS)1 reports
- HOUSE OF REPRESENTATIVES1 reports
- SENATE1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Chamber Hill Strategies | $50K | 1 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| JENNIFER BELL | Health Policy Advisor, Sen. Finance Committee; Legislative Assistant, Rep. John Thune (R-SD) | Q2 2026 |
| JENNIFER HOLLAND | Scheduler, Rep. Mary Kaptur (OH-09); Operations Director, Rep. Donald Norcross (NJ-01); Scheduler, Rep. Debbie Dingell (MI-06) | Q2 2026 |
| ZACHARY SCHULZ | Legislative Correspondent, Sen. Charles Grassley (R-IA) | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/19for Q2 | Chamber Hill Strategies | $50K |
| 07/10for Q2 | Chamber Hill Strategies | Under $5,000 |